Bausch+Lomb Results Presentation Deck
2Q23 Total Bausch+Lomb P&L¹ (Non-GAAP)²
Reported
Change
10%
6%
15%
10%
10%
(0 bps)
(13%)
Bausch + Lomb
Vision Care Revenue ³
Surgical Revenue
Pharmaceuticals Revenue ³
Total Revenue
Adj. Gross Profit²
Adj. Gross Margin²
R&D
R&D % of Revenue
Adj. SG&A²
Adj. SG&A % of Revenue
Adj. EBITA²
Depreciation
Stock Based Compensation
Adj. EBITDA 2,5
Adj. EBITDA Margin²
Adj. Net Income Attributable to
Bausch+Lomb²
Adj. EPS Attributable to Bausch + Lomb²
BAUSCH + LOMB
2Q23
$646M
$195M
$194M
$1,035M
$618M
59.7%
$85M
8.2%
$398M
38.5%
$135M
$37M
$18M
$179M
17.3%
$65M
$0.18
2Q224
$588M
$184M
$169M
$941 M
$562M
59.7%
$75M
8.0%
$362M
38.5%
$125M
$34M
$11M
$182M
19.3%
$103M
$0.29
(10%)
8%
9%
64%
(2%)
(37%)
1. Products with sales outside the United States impacted by F/X changes.
2. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.
3. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now
included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment
are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to
better align these products with the groupings of similar products. The net impact of these product movements was not material to the periods
Constant Currency
Change²
12%
7%
16%
12%
12%
(13%)
(12%)
12%
6%
64%
2%
(30%)
2Q23 FX Headwinds:
-$18M Revenue
-$25M Adj. EBITDA
Year-Over-Year Comparability
2Q23 results include stand-
alone costs associated with
the Bausch + Lomb separation
2Q22 results are not fully
burdened by stand-alone costs
presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.
4. 2022 results were not fully burdened by all stand-up costs associated with the separation.
5. Includes transactional FX and NCI. Currency headwind (translational and transactional) was -$25M to Adj. EBITDA for 2023. The 2Q22
transactional FX impact was a gain of $14M.
9View entire presentation